ArticleDiscover oncology2025
The preliminary multicenter retrospective study on the efficacy and safety of thermal ablation for follicular thyroid neoplasms ≤ 3 cm.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mid-Term Outcomes and Outcome Predictors after Radiofrequency Ablation for Indeterminate Thyroid Nodules Following Functional Imaging Screening: A Retrospective Cohort Study.Korean journal of radiology · 2026Article
- Pathology-based thermal ablation safety margin for follicular adenoma: a digital whole-slide study of follicular carcinoma invasion.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectivesTo evaluate the efficacy and safety of thermal ablation (TA) for follicular thyroid neoplasms (FTN) ≤ 3 cm.
methodsThis retrospective multicenter study enrolled 161 patients (131 females; mean age, 46 ± 15 years [range, 11-86]) who underwent TA for FTN ≤ 3 cm between January 2014 and October 2023 from eight centers in China. The median follow-up time was 12 months (IQR, 12-24 months). Based on the maximum diameter (MD) of the nodule, patients were divided into two groups: Group 1 (MD ≤ 2 cm) and Group 2 (2 < MD ≤ 3 cm). Post-ablation assessments encompassed evaluations of tumor size and volume changes, technical success rate, tumor disappearance, disease progression, complications, and risk factors associated with recurrent laryngeal nerve (RLN) injury.
resultsAll patients underwent complete ablation in a single session. The technical success rate was 100%. The mean volume reduction rate (VRR) of the ablation zone at 12 months was 78.11%. The VRR at 12 months was higher in Group 1 than that in Group 2 (Median VRR, 93.8% vs. 82.8%; P = 0.019). The complete tumor disappearance rate was 15.5% (25/161). Smaller tumors have a higher tumor disappearance rate (Group 1 vs Group 2 = 27.6% vs. 4.7%; P < 0.001). The disease progression rate was 2.5% (4/161), with no significant difference between Group 1 and Group 2 (P = 0.535). The complication rate was 3.1% (5/161), with no significant difference between Group 1 and Group 2 (P = 0.899). No risk factors were identified for RLN injury.
conclusionsThermal ablation is an effective and safe treatment option for patients with FTN ≤ 3 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.